Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo

Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone resorption can impair muscle contractility and prime the bone microenvironment to accelerate metastatic growth. We hypo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Wright, Laura E., Harhash, Ahmed A., Kozlow, Wende M., Waning, David L., Regan, Jenna N., She, Yun, John, Sutha K., Murthy, Sreemala, Niewolna, Maryla, Marks, Andrew R., Mohammad, Khalid S., Guise, Theresa A.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5352410/
https://ncbi.nlm.nih.gov/pubmed/28039445
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14139
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados